ChiCTR1900022657 版本V1.1 版本创建时间2019/04/20 17:44:48 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR1900022657 

最近更新日期:

Date of Last Refreshed on:

2019-04-20 17:39:30 

注册时间:

Date of Registration:

2019-04-20 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

置管长度对外周静脉留置针导管堵塞的干预效果

Public title:

Interventional effect of indwelling catheter length on blockage of external peripheral venous indwelling catheter: a randomized controlled trial

注册题目简写:

English Acronym:

研究课题的正式科学名称:

置管长度对外周静脉留置针导管堵塞的干预效果

Scientific title:

Interventional effect of indwelling catheter length on blockage of external peripheral venous indwelling catheter: a randomized controlled trial

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

张会会 

研究负责人:

张会会 

Applicant:

Zhang Huihui 

Study leader:

Zhang Huihui 

申请注册联系人电话:

Applicant telephone:

+86 18560082700

研究负责人电话:

Study leader's
telephone:

+86 18560082700

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

huihuizhang2014@163.com

研究负责人电子邮件:

Study leader's E-mail:

huihuizhang2014@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

山东省济南市历下区文化西路107号

研究负责人通讯地址:

山东省济南市历下区文化西路107号

Applicant address:

107 Wenhua Road West, Lixia District, Ji'nan, Shandong

Study leader's address:

107 Wenhua Road West, Lixia District, Ji'nan, Shandong

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

山东大学齐鲁医院

Applicant's institution:

Qilu Hospital of Shandong University

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2018220

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

山东大学齐鲁医院医学伦理委员会

Name of the ethic committee:

Ethics Committee on Medical Research of Shandong University Qilu Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2018-12-25 00:00:00

伦理委员会联系人:

李延青

Contact Name of the ethic committee:

Li Yanqing

伦理委员会联系地址:

山东省济南市历下区文化西路107号

Contact Address of the ethic committee:

107 Wenhua Road West, Lixia District, Ji'nan, Shandong

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

山东大学齐鲁医院

Primary sponsor:

Qilu Hospital of Shandong University

研究实施负责(组长)单位地址:

山东省济南市历下区文化西路107号

Primary sponsor's address:

107 Wenhua Road West, Lixia District, Ji'nan, Shandong

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

山东

市(区县):

济南

Country:

China

Province:

Shandong

City:

Ji'nan

单位(医院):

山东大学齐鲁医院

具体地址:

历下区文化西路107号

Institution
hospital:

Qilu Hospital of Shandong University

Address:

107 Wenhua Road West, Lixia District

经费或物资来源:

暂未确定

Source(s) of funding:

Not Yet

研究疾病:

甲状腺乳头状癌  

Target disease:

Papillary carcinoma of the thyroid gland

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

(1)探索最佳PIVCs置管长度; (2)探索置管长度对PIVCs导管堵塞的干预效果; (3)探索置管长度对降低PIVCs留置失败率、延长留置时间、降低使用PIVCs数目及相关费用的干预效果。  

Objectives of Study:

(1) Explore the optimal PIVCs catheter length; (2) Explore the effect of catheter length on the blockage of PIVCs catheters; (3) Explore the effect of catheter length on reducing the failure rate of PIVCs indwelling, extending the indwelling time, and reducing the number and related costs of using PIVCs.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

年龄为18~59岁;需要PIVCs治疗;预计PIVCs保留时间>24h;每名患者的PIVCs分析只纳入第1个。

Inclusion criteria

Aged 18 to 59 years; Requires PIVCs therapy; Estimated PIVCs retention time >24h; Only the first PIVCs analysis was included in each patient.

排除标准:

沟通障碍;使用肝素、速碧林等抗凝药;有血液系统疾病史、凝血功能异常的患者;感染性疾病患者。

Exclusion criteria:

Communication disorders; Heparin, spirulin and other anticoagulants were used; Patients with a history of diseases of the blood system and abnormal coagulation function; Patients with infectious diseases.

研究实施时间:

Study execute time:

From 2019-04-30 00:00:00 To 2021-10-19 00:00:00  

征募观察对象时间:

Recruiting time:

From 2019-10-07 00:00:00 To 2020-12-19 00:00:00

干预措施:

Interventions:

组别:

1

样本量:

388

Group:

1

Sample size:

干预措施:

留置针导管全部送入血管

干预措施代码:

Intervention:

The indwelling needle catheter was completely inserted into the blood vessel

Intervention code:

组别:

2

样本量:

388

Group:

2

Sample size:

干预措施:

留置针导管的5/6送入血管,余1/6,允许误差1mm

干预措施代码:

Intervention:

5/6 of the indwelling needle catheter was delivered into the blood vessel, leaving 1/6, with an allowable error of 1mm

Intervention code:

组别:

3

样本量:

388

Group:

3

Sample size:

干预措施:

留置针导管的2/3送入血管,余1/3,允许误差1mm

干预措施代码:

Intervention:

2/3 of the indwelling needle catheter was sent into the blood vessel, the remaining 1/3, with an allowable error of 1mm

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

山东 

市(区县):

济南 

Country:

China

Province:

Shandong

City:

Ji'nan

单位(医院):

山东大学齐鲁医院 

单位级别:

三级甲等综合医院 

Institution
hospital:

Qilu Hospital of Shandong University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

患者特征

指标类型:

附加指标

Outcome:

patient characteristics

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

PIVCs特征

指标类型:

附加指标

Outcome:

PIVCs characteristics

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

导管堵塞

指标类型:

主要指标

Outcome:

Catheter jam

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

各种原因导致的PIVC留置失败数

指标类型:

次要指标

Outcome:

Number of PIVC indwelling failures for various reasons

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

留置时间

指标类型:

次要指标

Outcome:

Indwelling time

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

治疗完成后使用PIVCs数目

指标类型:

次要指标

Outcome:

Number of PIVCs used after treatment

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

与使用PIVCs相关费用

指标类型:

次要指标

Outcome:

Costs associated with using the PIVCs

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

No

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由一名不参与研究对象筛选、干预及评估过程的人员使用SPSS软件生成随机数字序列,指定对照组、1/6组、1/3组,将随机数字依次放入按1-1164顺序编号的密封、不透光信封中,确保分配隐藏。由一名不清楚随机分组的研究人员筛选符合纳入标准的患者,获得知情同意后,根据入组顺序分配随机数字,据此将研究对象按1:1:1的比例随机分配到三组中。

Randomization Procedure (please state who generates the random number sequence and by what method):

SPSS software was used to generate a sequence of random numbers by a person who was not involved in the selection, intervention and evaluation of study subjects. The control group, 1/6 group and 1/3 group were designated, and the random numbers were placed in sealed, light-tight envelopes.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

open

Blinding:

open

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

none

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

收集患者的病案资料,使用SPSS软件进行数据管理。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Patients' medical records data were collected, and SPSS software was used for data management.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2019-04-20 17:39:20